{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:59:20Z","timestamp":1789189160202,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the efficacy and safety of rituximab (RTX) in Chinese patients with primary angiitis of the central nervous system (PACNS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Herein, we present the outcomes of 8 patients who received RTX for PACNS. Seven patients underwent a brain biopsy showing vasculitis, while the remaining patient had a digital subtraction angiogram and clinical findings highly suggestive of vasculitis. Clinical evaluation, laboratory tests, and imaging modalities were performed during the initial RTX administration and follow-up. The Expanded Disability Status Scale (EDSS) disability score was used to assess treatment response and degree of disability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age at diagnosis of the 8 patients (2 females) was 37.0\u202fyears. All patients had active disease when RTX treatment was initiated. Five of the eight patients had refractory disease, and received one or more conventional immunosuppressants (IS). Three patients had contraindications or refused conventional IS. Patients were followed up until their death or the final follow-up visit (median 18\u202fmonths; range: 0\u201340\u202fmonths). The median EDSS score at the last visit (median 3.0; range 0\u20139.5) was lower than before RTX administration (median 6.5; range 1.5\u20139.5). In 6 patients, RTX administration was associated with a marked reduction in the number of flare-ups. Two of the six patients developed infections: one with pneumonia, and the other with tuberculosis. In one patient, parenchymal gadolinium enhancement persisted, and a new lesion was found following three courses of RTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data suggest that RTX therapy may be an additional treatment option for Chinese patients with PACNS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1554989","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T03:04:02Z","timestamp":1742958242000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Rituximab treatment in Chinese patients with primary angiitis of the central nervous system"],"prefix":"10.3389","volume":"16","author":[{"given":"Yu-Zhen","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Lin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Hu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Cai","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(12)60069-5","article-title":"Adult primary central nervous system vasculitis","volume":"380","author":"Salvarani","year":"2012","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/art.39068","article-title":"Adult primary central nervous system vasculitis treatment and course: analysis of one hundred sixty-three patients","volume":"67","author":"Salvarani","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00401-012-0973-9","article-title":"Primary central nervous system vasculitis: pathology and mechanisms","volume":"123","author":"Giannini","year":"2012","journal-title":"Acta Neuropathol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e738","DOI":"10.1097\/MD.0000000000000738","article-title":"An update of the Mayo Clinic cohort of patients with adult primary central nervous system vasculitis: description of 163 patients","volume":"94","author":"Salvarani","year":"2015","journal-title":"Medicine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/art.38340","article-title":"Primary angiitis of the central nervous system: description of the first fifty-two adults enrolled in the French cohort of patients with primary vasculitis of the central nervous system","volume":"66","author":"de Boysson","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/23969873231190431","article-title":"European stroke organisation (ESO) guidelines on primary Angiitis of the central nervous system (PACNS)","volume":"8","author":"Pascarella","year":"2023","journal-title":"Eur Stroke J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1161\/STROKEAHA.118.021878","article-title":"Treatment and long-term outcomes of primary central nervous system Vasculitis","volume":"49","author":"de Boysson","year":"2018","journal-title":"Stroke"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"102907","DOI":"10.1016\/j.msard.2021.102907","article-title":"Rituximab for refractory primary angiitis of the central nervous system: experience in two patients","volume":"51","author":"Paramasivan","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/imj.13814","article-title":"Rituximab treatment in primary angiitis of the central nervous system","volume":"48","author":"Patel","year":"2018","journal-title":"Intern Med J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.autrev.2018.12.002","article-title":"Rituximab therapy for primary central nervous system vasculitis: a 6 patient experience and review of the literature","volume":"18","author":"Salvarani","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/VHRM.S488202","article-title":"Primary CNS Vasculitis - a Focussed review on treatment","volume":"20","author":"Kesav","year":"2024","journal-title":"Vasc Health Risk Manag"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00005792-198801000-00002","article-title":"Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria","volume":"67","author":"Calabrese","year":"1988","journal-title":"Medicine"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1161\/01.STR.30.8.1538","article-title":"Use of the Barthel index and modified Rankin scale in acute stroke trials","volume":"30","author":"Sulter","year":"1999","journal-title":"Stroke"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ana.26940","article-title":"Cortical microhemorrhage presentation of small vessel primary Angiitis of the central nervous system","volume":"96","author":"Guo","year":"2024","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/0028-3886.253578","article-title":"Primary angiitis of the central nervous system: clinical profiles and outcomes of 45 patients","volume":"67","author":"Sundaram","year":"2019","journal-title":"Neurol India"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.55563\/clinexprheumatol\/a9886f","article-title":"Clinical characteristics, brain magnetic resonance imaging findings and diagnostic approach of the primary central nervous system vasculitis according to angiographic classification","volume":"41","author":"Shimoyama","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00415-019-09285-1","article-title":"Relapse rates and long-term outcome in primary angiitis of the central nervous system","volume":"266","author":"Schuster","year":"2019","journal-title":"J Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3969\/j.issn.1006-2963.2017.04.001","article-title":"Chinese expert consensus on diagnosis and treatment of primary central nervous system vasculitis","volume":"24","year":"2017","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e2243799","DOI":"10.1001\/jamanetworkopen.2022.43799","article-title":"Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with Polyangiitis","volume":"5","author":"Puechal","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s13311-015-0402-6","article-title":"Anti-B-cell therapies in autoimmune neurological diseases: rationale and efficacy trials","volume":"13","author":"Alexopoulos","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/PAS.0b013e318181e097","article-title":"Biopsy findings in primary angiitis of the central nervous system","volume":"33","author":"Miller","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1097\/RHU.0000000000001075","article-title":"Relapsing primary central nervous system Vasculitis treated with rituximab","volume":"26","author":"Messmer","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/14712598.2020.1748597","article-title":"Rituximab treatment of ANCA-associated vasculitis","volume":"20","author":"Raffray","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.clineuro.2017.03.006","article-title":"Primary central nervous system vasculitis and its mimicking diseases - clinical features, outcome, comorbidities and diagnostic results - a case control study","volume":"156","author":"Becker","year":"2017","journal-title":"Clin Neurol Neurosurg"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/cei.12221","article-title":"Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls","volume":"175","author":"Berlit","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"117422","DOI":"10.1016\/j.jns.2021.117422","article-title":"Primary central nervous system vasculitis - an update on diagnosis, differential diagnosis and treatment","volume":"424","author":"Kraemer","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"13494","DOI":"10.1038\/s41598-022-17869-7","article-title":"Primary CNS vasculitis (PCNSV): a cohort study","volume":"12","author":"Agarwal","year":"2022","journal-title":"Sci Rep"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1554989\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T03:04:11Z","timestamp":1742958251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1554989\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":32,"alternative-id":["10.3389\/fneur.2025.1554989"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1554989","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"article-number":"1554989"}}